Posters presented at Infectious Disease Week (IDWeek) 2025 Annual Meeting found Lenacapavir does not appear to cause any clinically significant effects in the pharmacokinetics of long-acting hormonal contraceptives or gender-affirming hormone therapy. David Koren, PharmD, MPH, BCIDP, AAHIVP, FIDSA, Infectious Disease Clinical Pharmacist at Temple University Hospital, told Medscape the findings increase options so the right person can be on the right dose of the medication, whether it’s for contraception or gender-affirming therapy.
Weather Alert: A major winter storm is likely to impact the Philadelphia region this weekend into Monday. Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH